Merck Serono announced that the FDA has approved EMD Serono‘s GONAL-f RFF Redi-ject (recombinant follitropin alfa) injection, a disposable prefilled drug injector pen indicated for the subcutaneous ...
GONAL-f (follitropin alfa injection) is a recombinant human follicle-stimulating hormone (r-hFSH) approved for the treatment female infertility and a rare form of male infertility. Merck announced ...
Urofollitropin (Gonal -F FBM) is a human follicle-stimulating hormone, prescribed in combination with HCG hormone for infertility in women who have not responded to other therapy. It stimulates the ...
The Gonal-f ® RFF Redi-ject™ will be available in December 2013 in three pen sizes: 300 IU, 450 IU and 900 IU. For more information about the Gonal-f ® RFF Redi-ject™, please call Fertility Lifelines ...
GENEVA, Switzerland, July 16 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the Japanese Ministry of Health, Labor and Welfare has granted approval to ...
DARMSTADT, Germany — The Food and Drug Administration has approved a pre-filled injector pen made by EMD Serono for infertile women, the company said Friday. The drug maker — the U.S. subsidiary of ...
President Donald Trump on Thursday announced that EMD Serono, a Massachusetts-based healthcare company, will lower the price of Gonal-f, a widely used fertility medication, as part of a broader ...
Merck KGaA, whose sales of fertility drugs have benefited from competitor supply problems, will now have even more of its Gonal-f fertility drug to sell. The German company said today that it has ...
IVF treatment with Ferring’s Menopur yields a significantly higher live birth rate than that achieved with Serono’s recombinant follicle stimulating hormone product Gonal F (follitropin alfa), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results